WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) reported a second-quarter net loss of $15.4 million and a year-to-date loss of $30.5 million, as the company continues to invest in advancing a pipeline focused on immuno-inflammatory (I&I) diseases.
The biopharmaceutical firm posted $1.8 million in revenue for the second quarter of 2025, down from $2.8 million a year ago. The decline was attributed to the 2024 sale of a portion of its royalty stream from Eli Lilly to the Ontario Municipal Employees Retirement System (OMERS).
Research and development expenses rose to $11.4 million in the quarter, up from $8.8 million in Q2 2024, driven by costs related to ongoing clinical trials for multiple candidates, including bosakitug and ATI-052. General and administrative costs increased modestly to $5.4 million, reflecting higher personnel expenses.
Despite widening losses, Aclaris emphasized its strong cash position, reporting $180.9 million in cash and marketable securities at the end of June. The company expects this capital will fund operations into the second half of 2028.
The quarter marked notable pipeline progress. The company achieved primary and secondary endpoints in a Phase 2a trial for ATI-2138, its investigational ITK/JAK3 inhibitor for moderate-to-severe atopic dermatitis (AD). Management believes the results validate ITK as a target and show ATI-2138 may offer efficacy comparable to approved JAK inhibitors with a better safety profile.
Patient dosing has begun in Phase 2 trials for bosakitug, a monoclonal antibody targeting TSLP, and in Phase 1a for ATI-052, a bispecific antibody targeting TSLP and IL-4R. Top-line results for both are expected in 2026.
CEO Dr. Neal Walker said the pipeline progress marks “a period of strong execution” and emphasized the company’s long-term strategy is fully funded. He also noted ongoing efforts to identify non-dilutive financing to extend the runway further.
Additionally, Aclaris announced that Roland Kolbeck, Ph.D., has been named Chief Scientific Officer, succeeding Joe Monahan, Ph.D., who will remain in an advisory role until early 2026.
The company continues to focus on advancing its next-generation therapies for immune-mediated skin conditions while maintaining capital discipline and strengthening its leadership team.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.